307 related articles for article (PubMed ID: 26194691)
1. Increased thrombin generation in women with polycystic ovary syndrome: A pilot study on the effect of metformin and oral contraceptives.
Glintborg D; Sidelmann JJ; Altinok ML; Mumm H; Andersen M
Metabolism; 2015 Oct; 64(10):1272-8. PubMed ID: 26194691
[TBL] [Abstract][Full Text] [Related]
2. The benefit-to-risk ratio of common treatments in PCOS: effect of oral contraceptives versus metformin on atherogenic markers.
Christakou C; Kollias A; Piperi C; Katsikis I; Panidis D; Diamanti-Kandarakis E
Hormones (Athens); 2014; 13(4):488-97. PubMed ID: 25555182
[TBL] [Abstract][Full Text] [Related]
3. Body composition is improved during 12 months' treatment with metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome.
Glintborg D; Altinok ML; Mumm H; Hermann AP; Ravn P; Andersen M
J Clin Endocrinol Metab; 2014 Jul; 99(7):2584-91. PubMed ID: 24742124
[TBL] [Abstract][Full Text] [Related]
4. The effects of 2 mg chlormadinone acetate/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome.
Vieira CS; Martins WP; Fernandes JB; Soares GM; dos Reis RM; de Sá MF; Ferriani RA
Contraception; 2012 Sep; 86(3):268-75. PubMed ID: 22464410
[TBL] [Abstract][Full Text] [Related]
5. Increased plasma viscosity in young women with polycystic ovary syndrome using an oral contraceptive containing 35 μg ethinyl estradiol and 2 mg cyproterone acetate.
Markantes G; Saltamavros AD; Vervita V; Armeni AK; Karela A; Adonakis G; Decavalas G; Georgopoulos NA
Gynecol Endocrinol; 2011 Dec; 27(12):971-7. PubMed ID: 21501001
[TBL] [Abstract][Full Text] [Related]
6. Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity.
Ibáñez L; De Zegher F
Hum Reprod; 2004 Aug; 19(8):1725-7. PubMed ID: 15229206
[TBL] [Abstract][Full Text] [Related]
7. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study.
Elter K; Imir G; Durmusoglu F
Hum Reprod; 2002 Jul; 17(7):1729-37. PubMed ID: 12093831
[TBL] [Abstract][Full Text] [Related]
8. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study.
Morin-Papunen L; Vauhkonen I; Koivunen R; Ruokonen A; Martikainen H; Tapanainen JS
J Clin Endocrinol Metab; 2003 Jan; 88(1):148-56. PubMed ID: 12519844
[TBL] [Abstract][Full Text] [Related]
9. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome.
Morin-Papunen L; Rautio K; Ruokonen A; Hedberg P; Puukka M; Tapanainen JS
J Clin Endocrinol Metab; 2003 Oct; 88(10):4649-54. PubMed ID: 14557435
[TBL] [Abstract][Full Text] [Related]
10. Increased follistatin levels after oral contraceptive treatment in obese and non-obese women with polycystic ovary syndrome.
Chen MJ; Yang WS; Chen HF; Kuo JJ; Ho HN; Yang YS; Chen SU
Hum Reprod; 2010 Mar; 25(3):779-85. PubMed ID: 20093255
[TBL] [Abstract][Full Text] [Related]
11. Endogenous thrombin potential in polycystic ovary syndrome: the association to body mass index, insulin resistance, and inflammation.
Aziz M; Sidelmann JJ; Wissing ML; Faber J; Skouby SO
Gynecol Endocrinol; 2015; 31(9):720-4. PubMed ID: 26291802
[TBL] [Abstract][Full Text] [Related]
12. Low-dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycystic ovary syndrome.
Ibáñez L; de Zegher F
Hum Reprod; 2003 Jan; 18(1):57-60. PubMed ID: 12525441
[TBL] [Abstract][Full Text] [Related]
13. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
Wu J; Zhu Y; Jiang Y; Cao Y
Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
[TBL] [Abstract][Full Text] [Related]
14. Body composition in lean women with polycystic ovary syndrome: effect of ethinyl estradiol and drospirenone combination.
Aydin K; Cinar N; Aksoy DY; Bozdag G; Yildiz BO
Contraception; 2013 Mar; 87(3):358-62. PubMed ID: 22898361
[TBL] [Abstract][Full Text] [Related]
15. The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia.
Panidis D; Georgopoulos NA; Piouka A; Katsikis I; Saltamavros AD; Decavalas G; Diamanti-Kandarakis E
Gynecol Endocrinol; 2011 Aug; 27(8):587-92. PubMed ID: 20836726
[TBL] [Abstract][Full Text] [Related]
16. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
[TBL] [Abstract][Full Text] [Related]
17. Effects of metformin or an oral contraceptive containing cyproterone acetate on serum c-reactive protein, interleukin-6 and soluble vascular cell adhesion molecule-1 concentrations in women with polycystic ovary syndrome.
Dardzińska JA; Rachoń D; Kuligowska-Jakubowska M; Aleksandrowicz-Wrona E; Płoszyński A; Wyrzykowski B; Lysiak-Szydłowska W
Exp Clin Endocrinol Diabetes; 2014 Feb; 122(2):118-25. PubMed ID: 24554512
[TBL] [Abstract][Full Text] [Related]
18. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity.
Ibáñez L; de Zegher F
J Clin Endocrinol Metab; 2004 Apr; 89(4):1592-7. PubMed ID: 15070917
[TBL] [Abstract][Full Text] [Related]
19. Effects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: influence of obesity and smoking.
Luque-Ramírez M; Mendieta-Azcona C; del Rey Sánchez JM; Matíes M; Escobar-Morreale HF
Eur J Endocrinol; 2009 Mar; 160(3):469-80. PubMed ID: 19139031
[TBL] [Abstract][Full Text] [Related]
20. Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
Fruzzetti F; Perini D; Lazzarini V; Parrini D; Gambacciani M; Genazzani AR
Fertil Steril; 2010 Oct; 94(5):1793-8. PubMed ID: 19931080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
